Johan Richter

9PUBLICATIONS
54CO-AUTHORS
Molecular targetsHaematological tumoursEpidemiological modellingCancer therapy (excl. chemotherapy and radiation therapy)Human rights and justice issues (excl. law)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 18, 2026
Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study.

|Jul 11, 2025
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.

Jane F Apperley, Dragana Milojkovic, Nicholas C P Cross

|Jul 10, 2024
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.

Fabio Efficace, Francois-Xavier Mahon, Johan Richter

|Feb 28, 2024
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.

Hjalmar Flygt, Stina Söderlund, Johan Richter

|Jan 26, 2024
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.

Hjalmar Flygt, Stina Söderlund, Johan Richter

|Jan 03, 2024
How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to R.P. Gale and J. Chen.

Markus Pfirrmann, Susanne Saussele, François-Xavier Mahon

Pageof 2

Frequent Collaborators

8 joint publications

Susanne Saussele

4 joint publications

Henrik Hjorth-Hansen

4 joint publications

Markus Pfirrmann

3 joint publications

Hjalmar Flygt